Bioequivalence study of ezetimibe and atorvastatin tablets versus film‑coated tablets in healthy volunteers

1 1 1

What is this study about?

A study is being done with people who are healthy and do not have any illness. The participants will take a single dose of a combined medication that contains ezetimibe and atorvastatin, which are medicines used to lower cholesterol levels in the blood. Two different tablet forms of this combination are being compared: one is a regular tablet and the other is a film‑coated tablet.

The main goal of the study is to see if the two tablet forms deliver the medicines to the body in the same amount and at the same speed, a concept known as bioequivalence. This helps determine whether the new tablet works just as well as the already available version.

Volunteers will come to the study site, fast for a short period, take one of the tablets, and then have a few short check‑ins where a small blood sample may be taken to measure how much of the medicines entered the bloodstream. After a wash‑out period, the participants will return to receive the other tablet and repeat the same short monitoring. The whole process involves only a single dose of each tablet and a brief follow‑up, without any long‑term treatment.

Who Can Join the Study?

Who Cannot Join the Study?

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Hvhggfpo Ujgusosusefaj Db Ln Pfagqliv Madrid Spain

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Spain Spain
Not recruiting
30.08.2023

Trial locations

Trial ID:
2023-507226-16-00
Protocol code:
N-EZEATO-23-283
Trial Phase:
Human Pharmacology (Phase I) – Bioequivalence Study

Other Trials to Consider

  • Evaluation of mRNA-4359 Monotherapy and Combined Pembrolizumab Therapy in Advanced Solid Tumors: A Phase 1/2 Clinical Trial

    Recruiting

    1 1 1
    Germany Italy Poland Spain
  • Phase 1/2 Evaluation of Zilovertamab Vedotin in PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma

    Recruiting

    1 1 1
    Denmark Italy The Netherlands Spain